Tuesday, 25 February 2020

Chemotherapy Market SWOT Analysis, Major Key Players Revenue, Analysis and Forecasts to 2023

Market Scenario:
Chemotherapy Market 2019 offered by Market Research Future (MRFR), The Global Chemotherapy Market is Expected to register a CAGR of 11.50% to reach USD 56,491.59 Million by 2024. Global Chemotherapy Industry by Drug Class, Indication, Route of Drug Administration and End-User and Forecast till 2024
The increasing prevalence of cancer, increasing expenditure on oncology medicine and research, and reimbursements and growing health insurance are driving the growth of the global chemotherapy market. 
Market Dynamics
The Global Chemotherapy Market has been largely benefited by the increasing demand for chemotherapy products across the world. Increasing prevalence of cancer; increasing expenditure on oncology medicine and research, and reimbursements and growing health insurance are expected to spur market growth during the forecast period. Moreover, the patent expiry of leading drugs, government initiatives, and increasing public awareness about various diseases and treatment options are further expected to boost the growth of the global chemotherapy market during the review period.
Chemotherapy is one of the types of cancer treatment, which includes the use of one or more chemotherapeutic agents such as anti-cancer drugs. The treatment prevents the division of cancer cells and the growth of cancer cells by killing dividing cells. It is used for the treatment of various types of cancers such as lung cancer, breast cancer, leukemia, myeloma, sarcoma, lymphoma, ovarian cancer, and others.
Segmentation
The Global Chemotherapy has been segmented into major four segments, including drug class, route of administration, indication, and end user.
On the basis of drug class, the market is segmented into alkylating agents, mitotic inhibitors, antimetabolites, topoisomerase inhibitors, and antitumor antibiotic. The alkylating agents segment is expected to lead the market and register a substantial CAGR to reach USD 20,360.32 million by the end of 2024 and projected to exhibit the highest CAGR of 11.83% from 2019 to 2024.
Furthermore, based on indication, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, lymphoma, leukemia, ovarian cancer, and others.  Lung cancer accounted for the largest market share and expected to grow with the CAGR of 11.88% during the forecast period.
On the basis of route of administration, the market is segmented into intravenous, oral, subcutaneous, intra-muscular, intravesicular, topical, intraperitoneal, and intraventricular/intrathecal. Intravenous accounted for the largest market share. However, the oral segment is expected to grow at the fastest CAGR of 11.95% during the forecast period.
On the basis of end user, the market is segmented into, specialty centers, hospitals & clinics, others
Key Players
The prominent players in the global chemotherapy market are Johnson & Johnson Services Inc (US), GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (US), Merck & Co. Inc. (US), Sanofi S.A. (France), Celgene Corporation (US) and Bristol-Myers Squibb Company (US).
Regional Analysis
Geographically the chemotherapy market is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Americas accounted for the largest market share of 41.04% in 2018, and the regional market is projected to register a CAGR of 10.88%during the forecast period. North America is one of the leading markets in the region, accounting for the largest market share during the review period.  
The European market is estimated to exceed USD 18,292.73 Million by 2024. The accessibility to advanced treatment facilities, rising government initiatives to promote research to find a cure to the increasing number of cancer cases, and growing healthcare expenditure are driving the growth of the chemotherapy market in the region. Germany is the major contributor to the growth of the regional market, followed by France.
The market in Asia-Pacific is expected to be the fastest growing market. This high growth is mainly attributed to the increasing R&D funding by developing countries such as China and India for the development of the healthcare sector. Various other factors that influence the growth of the market include growing incidence of cancer, aging population, increasing demand for advanced therapies, patent expiry of leading drugs, government initiatives, and increasing public awareness about various diseases and treatment options.
The Middle East & Africa commands the least market share of the chemotherapy market, owing to fewer developments and extremely low income but, is expected to grow with better chemotherapy treatments. As the population is rapidly aging, cancer treatment is expected to increase in this region
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Monday, 24 February 2020

Nuclear Imaging Devices market growth and regional forecast 2019 - 2023

The global nuclear imaging devices market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 2490 million in 2018 and is projected to register a CAGR of 5.2% over the forecast period.
Nuclear imaging, also known as molecular imaging, is a scanning procedure in which a small amount of radioactive material is injected into a vein, and then pictures are taken with the help of a gamma camera.
The increasing prevalence of cardiovascular disorders is one of the key factors driving the nuclear imaging devices market. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults were dealing with at least one type of cardiovascular disease.
Various other factors such as the advancements in radiotracers, acceptance of nuclear imaging devices in ambulatory settings, increasing geriatric population, untapped emerging markets, rise in regulatory approvals, and increasing investment on diagnostic imaging centers are also expected to propel the growth of the market.
However, the high cost of the nuclear imaging device, shorter half-life of radiopharmaceuticals can hamper market growth over the forecast period.
Segmentation
The global nuclear imaging devices market is segmented based on technology, application, end user, and region.
The global market for nuclear imaging devices, by technology, is segmented into positron emission tomography (PET), single photon emission computed tomography (SPECT), and planar scintigraphy. The single-photon-emission computed tomography (SPECT) are further classified as hybrid SPECT systems and standalone SPECT systems.
Based on application, the market is segmented into oncology, cardiology, neurology, and others.
Based on end user, the market is segmented into hospitals, diagnostic imaging centers, and others.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The nuclear imaging devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European nuclear imaging devices market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The nuclear imaging devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The nuclear imaging devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
  • Philips Healthcare
  • General Electric Company
  • Digirad Corporation
  • Neusoft Medical Systems Co., Ltd.
  • Cannon Inc.
  • Surgiceye GmbH
  • CMR Naviscan
  • Mediso Medical Imaging Systems Ltd.
  • Agfa-Gevaert Group
  • DDD-Diagnostic A/S
  • Segamicorp
  • Spectrum Dynamics Medical
Regional Market Summary
The Americas dominated the global market for nuclear imaging devices owing to the rising geriatric population within the region. As per the data suggested by the United Census Bureau, by 2060, the US is projected to grow by 79 million people, from about 326 million today to 404 million. The population is projected to cross the 400-million threshold in 2058. Rising Participation of market players is also strongly impacting the growth of the Americas nuclear imaging devices market. For instance, in 2018, GE Healthcare highlighted the upgradable configuration of Discovery MI at the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Discovery MI is the highest sensitivity digital PET in the industry that helps delivering the vision of precision health, giving personalized, and quantitative data to clinicians.
In 2018, it was estimated that Europe stood second in the global nuclear imaging market. Technological advancements, along with the availability of funding opportunities in research and innovation, will support market growth. The rising awareness about the nuclear bone scan and radiology nuclear medicine is also boosting the market growth.
Asia-Pacific (APAC) is expected to represent the phenomenal market growth throughout the forecast period due to rising prevalence of chronic conditions, growing awareness about nuclear imaging, and increasing healthcare expenditure. During 2016-2017, Australia spent nearly USD181 billion on health, which is more than USD 7,400 per person and 10% of overall economic activity.
On the other hand, the Middle East and Africa held the least share in the global nuclear imaging devices market due to the low economic development, especially within the African region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Blood Screening market to receive overwhelming hike in revenues by 2023

The Global Blood Screening Market is expected to register a growth of significant CAGR 9.8% during the forecast period (2018–2023).
Blood Screening is a medical procedure where the donated blood is tested for the presence or absence of HIV, HBV, HCV, malaria, syphilis, and for various other infectious diseases. The donated blood is screened for these infectious diseases to lessen the risk of transfusion-transmitted infections (TTIs).
Factors such as increasing number of blood donations and blood donors, increasing awareness about the safety of donated blood are some major factors influencing the growth of blood screening market. Moreover, increasing affordability and adoption of nucleic acid test (NAT) for blood screening, and growing prevalence of infectious diseases is also boosting the growth of this market. Nevertheless, principal expenditure and the operational costs of NAT devices, lack of regulations for NAT in developing countries, and the advent of alternative technologies are limiting the growth of market. Additionally, china’s and India’s market are observed as rising economies due to the introduction of pathogen reduction technology, and demand of multiplex tests.
Segmentation:
The Global Blood Screening Market has been segmented on the devices, service providers, application, end users.
On the basis of technology, the market has been classified as nucleic acid amplification test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, next-generation sequencing (NGS), western blotting. The nucleic acid amplification test is segmented in to transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR). The enzyme-linked immunosorbent assay is segmented in to ELISA market, by platform and ELISA market, by generationOn the basis of products and services, the market has been classified as reagent and kits, enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides, and solutions, immunosorbents, instruments and software and services. The reagent and kits have been segmented in to NAT reagents & kits, ELISA reagents & kits. The instruments have been segmented in to rental purchase and outright purchase.
On the basis of end users, the market has been classified as hospitals, clinics, research institutes and academic centers, blood banks and others.On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European arrhythmia monitoring devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The Blood Screening Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. TheBlood Screening Marketin the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary:In the Blood Screening Market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into drugs. According to America’s Blood organization 1 in 7 people entering the hospitals needs blood. According to American Red Cross, less than 38 percent of the population is eligible to give blood or platelets. According to Centers for Disease Control and Prevention (CDC), there are more than 9.5 Million blood donors in the United States and an estimated 5 million patients who receive blood annually, resulting in a total of 14.6 Million transfusions per year.
The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to World Health Organization (WHO) the average number of donations across the European Region ranges from 6 to 67.6 per 1000 inhabitants, with Demark reporting the highest blood donation rate.
Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure. Countries in the Asia pacific region, such as China and India, are the hotspots for investment opportunities due to treatment and research activities, growing number of partnerships and healthcare modernization, growing rate of diagnosis, quality improvisations.
The market in the Middle East & Africa is expected to account for the smallest share of the global blood screening market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.
Key Players:
Some of the key players in the Global Blood Screening Market Grifols, F. Hoffmann-La Roche, Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthineers (A Subsidiary of Siemens AG), Ortho Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Beckman Coulter (A Subsidiary of Danaher Corporation) and Becton, Dickinson and Company.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Oral Thin Film Drugs market - positive long-term growth outlook 2023

Market Synopsis
Oral thin films (OTF) are an innovative method discovered by pharmaceutical scientists for delivering drugs orally or bucally (absorption or dissolution in the mouth). OTF drugs have gained popularity owing to its rapid dissolution on contact with saliva. The global oral thin film drugs market is predicted to exhibit a 10.50% CAGR from 2018 to 2023 (forecast period), as per the latest report by Market Research Future (MRFR). This can be credited to the expanding geriatric population and their need for advanced drug delivery methods to keep chronic diseases such as diabetes at bay. Continuous investment in research and development (R&D) by companies to create easily dissolvable solutions for other diseases is expected to spur market growth over the forecast period. Introduction of OTF drugs in developing countries can act as a good revenue source for the OTF drugs market.
Report Overview
The report provides an accurate overview of the market complete with statistical graphs to support the forecasted figures. Our analysts make insightful predictions regarding the scope of the market and its future prospects. MRFR’s report includes a thorough analysis of the global oral thin film drugs market segmented on the basis of product, disease indication, distribution channel, and region. Numerous growth strategies undertaken by companies as well as the latest trends driving the market are outlined in the report. The market share of all prominent players and their current position is discussed in minute detail. It analyzes new revenue sources for players and emphasizes on the various strategies implemented by players.
Segment Overview
The global oral thin film drugs market is segmented by product, disease indication, and distribution channel. By product, the market is divided into sublingual and fast dissolving buccal film.  By disease indication, the market is segmented into opioid dependence, migraine, schizophrenia, and nausea and vomiting, and others. Distribution channel discussed in the report include hospital pharmacies, retail pharmacies, online drug stores, and others. The segments covered in the oral thin film drugs market report are analyzed with respect to four main regions namely – Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA), with respective country-level market sizing. The report discusses in detail the various players residing in these regions and their respective strategies to climb up the market ladder.
Competitive Landscape
Prominent players in the oral thin film drugs market include Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), CURE Pharmaceutical (U.S.), Novartis AG (Switzerland), LTS Lohmann Therapie-Systeme AG (Germany), GlaxoSmithKline Plc (U.K.), and Indivior Plc (U.S.).
The report offers a comprehensive analysis on the profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, expansion techniques, and latest R&D initiatives are discussed in minute detail.
Research Methodology
At MRFR, our research analysts conduct a thorough objective analysis of the market while creating market reports by adhering to a rigorous set of standards which allow a truly comprehensive view of the market. Use of primary research strategies such as interviews can lead to accrual of highly relevant data. Secondary research entails a thorough analysis of past and present trends in a forward-looking manner.
In addition, market size estimation and validation use both top-down & bottom-up approaches to obtain data from the value and supply chain. The balanced number of buyers and suppliers will result in a negligible demand-supply gap. Credible resources are accessed and verified by analysts to understand the nuances of market factors with consistency. Competent data analysts use strong analytical tools to ascertain accurate analysis of very relevant parameters in an effort to provide clients with a conclusive and dependable view of the future.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Respiratory Care Devices market with global industry analysis by 2019 – 2023

Global Sterilization Equipment Market: By Product (Heat Sterilization, Low-Temperature Sterilization, and Others), by Technology (Gravity, Vacuum, Steam, Forced Convention), and by End-User (Pharmaceutical Companies and Others)–Global Forecast Till 2023
Market Scenario
The Global Respiratory Care Devices market is expected to grow during the forecast period (2018–2023) at a CAGR ~7.0%.
Sterilization is a critical procedure in the healthcare industry and used to control the microbial populations which can affect the product quality. Numerous sterilization techniques are available in the market to control microbial growth. The increasing cases of hospital-acquired infections, an increasing number of surgical procedures, and increasing awareness about food sterilization and disinfection are expected to drive the growth of the market. Moreover, increasing research and development activities and technological advancements in sterilization techniques and increasing cases of chronic wounds are contributing to the growth of the market. According to a survey conducted by the American Professional Wound Care Association (2017), chronic non-healing wounds impact nearly 15% of Medicare beneficiaries (8.2 million) and a conservative estimate of the annual cost is USD 28 billion.
The rising cost of Respiratory Care Devices, stringent government regulations and lack of awareness may hamper the growth of the market during the assessment period.
Segmentation
The global Respiratory Care Devices market has been segmented on the basis of product, technology, and end–user.
On the basis of product, the market has been classified as heat sterilization, low-temperature sterilization, filtration sterilization, ionizing radiation sterilization. The heat sterilization segment has been further divided into dry heat sterilization and moist heat sterilization. The Low-temperature sterilization segment has been further divided into ethylene oxide sterilization, hydrogen peroxide sterilization, and others. The ionizing radiation sterilization segment has been classified as electron beams and gamma rays.
The technology segment has been divided into steam, forced convention, vacuum, gravity, and natural convection.
The market, by end–user, has been segmented into hospitals & clinics, research institutes, pharmaceutical companies, food & beverage industry, medical device companies, and other end–users.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Respiratory Care Devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European Respiratory Care Devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The Respiratory Care Devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Respiratory Care Devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas is likely to dominate the global Respiratory Care Devices market owing to the increasingly strict sterility guidelines, increase in the number of surgical procedures due to rising geriatric population, the presence of a well-established healthcare system and adoption of highly advanced technology. According to the article published in 2016 by the National Council on Aging, about 80 percent of older adults have at least one chronic disease and 68 percent have at least two.
The European market is expected to be the second-largest Respiratory Care Devices market. The market growth in this region can be attributed to the increasing government expenditure on healthcare and increasing research activities in the life sciences sector. Moreover, a growing number of road accidents in Europe region are contributing to the growth of the market in this region. According to an article published in 2015 by the World Health Organization (WHO), In Europe per year more than 2 million people suffer from road accidents and injuries related to it.
Asia-Pacific is expected to be the fastest-growing Respiratory Care Devices market during the forecast period owing to the increasing prevalence of chronic diseases, increasing number of hospitals and research institutes in Asia and growth in healthcare and biotech industry. According to the World Health Organization (WHO), the geriatric population in China in the year 2013 was 22.6 million, which is expected to show a massive growth and reach 90.4million by 2050.
The market in the Middle East & Africa is expected to hold the smallest share of the global Respiratory Care Devices market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor research and healthcare facilities.
Key Players
Some of the key players in the global Respiratory Care Devices market are 3M, STERIS plc., Getinge AB, Sotera Health, Advanced Sterilization Products (Division of Ethicon), Belimed, Anderson Products, Boekel Scientific, Celitron Medical, Technologies Kft., Fedegari Autoclavi S.p.A., Cantel Medical., LTE Scientific, Merck & Co., Inc, Midmark Corporation, and MMM Group.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Sterilization Equipment market global industry by regions, type & applications during 2020-2023

Market Scenario
The Globalsterilization equipment market is expected to grow during the forecast period (2018–2023) at a CAGR ~7.0%.
Sterilization is a critical procedure in the healthcare industry and used to control the microbial populations which can affect the product quality. Numerous sterilization techniques are available in the market to control microbial growth. The increasing cases of hospital-acquired infections, an increasing number of surgical procedures, and increasing awareness about food sterilization and disinfection are expected to drive the growth of the market. Moreover, increasing research and development activities and technological advancements in sterilization techniques and increasing cases of chronic wounds are contributing to the growth of the market. According to a survey conducted by the American Professional Wound Care Association (2017), chronic non-healing wounds impact nearly 15% of Medicare beneficiaries (8.2 million) and a conservative estimate of the annual cost is USD 28 billion.
The rising cost of sterilization equipment, stringent government regulations and lack of awareness may hamper the growth of the market during the assessment period.
Segmentation
The global sterilization equipment market has been segmented on the basis of product, technology, and end–user.
On the basis of product, the market has been classified as heat sterilization, low-temperature sterilization, filtration sterilization, ionizing radiation sterilization. The heat sterilization segment has been further divided into dry heat sterilization and moist heat sterilization. The Low-temperature sterilization segment has been further divided into ethylene oxide sterilization, hydrogen peroxide sterilization, and others. The ionizing radiation sterilization segment has been classified as electron beams and gamma rays.
The technology segment has been divided into steam, forced convention, vacuum, gravity, and natural convection.
The market, by end–user, has been segmented into hospitals & clinics, research institutes, pharmaceutical companies, food & beverage industry, medical device companies, and other end–users.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The sterilization equipment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European sterilization equipment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The sterilization equipment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The sterilization equipment market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas is likely to dominate the global sterilization equipment market owing to the increasingly strict sterility guidelines, increase in the number of surgical procedures due to rising geriatric population, the presence of a well-established healthcare system and adoption of highly advanced technology. According to the article published in 2016 by the National Council on Aging, about 80 percent of older adults have at least one chronic disease and 68 percent have at least two.
The European market is expected to be the second-largest sterilization equipment market. The market growth in this region can be attributed to the increasing government expenditure on healthcare and increasing research activities in the life sciences sector. Moreover, a growing number of road accidents in Europe region are contributing to the growth of the market in this region. According to an article published in 2015 by the World Health Organization (WHO), In Europe per year more than 2 million people suffer from road accidents and injuries related to it.
Asia-Pacific is expected to be the fastest-growing sterilization equipment market during the forecast period owing to the increasing prevalence of chronic diseases, increasing number of hospitals and research institutes in Asia and growth in healthcare and biotech industry. According to the World Health Organization (WHO), the geriatric population in China in the year 2013 was 22.6 million, which is expected to show a massive growth and reach 90.4million by 2050.
The market in the Middle East & Africa is expected to hold the smallest share of the global sterilization equipment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor research and healthcare facilities.
Key Players
Some of the key players in the global sterilization equipment market are 3M, STERIS plc., Getinge AB, Sotera Health, Advanced Sterilization Products (Division of Ethicon), Belimed, Anderson Products, Boekel Scientific, Celitron Medical, Technologies Kft., Fedegari Autoclavi S.p.A., Cantel Medical., LTE Scientific, Merck & Co., Inc, Midmark Corporation, and MMM Group.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Endometrial Cancer market industry 2020 product specification, growth drivers, applications and forecast to 2023

Market Scenario
The abnormal growth of endometrium cells in the uterus is termed as endometrial cancer which is also known as uterine cancer. Endometrial cancer is diagnosed at an early stage as women experience abnormal vaginal bleeding. It is reported that endometrial cancer is the sixth most common cancer in women all over the world. The endometrial cancer market is expected to witness a tremendous growth owing to the rising prevalence of endometrial cancer. Other key factors such as the growing obesity among women, increase in menopausal hormone therapy, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, increasing occurrence of Polycystic Ovarian Syndrome (PCOS), and increasing prevalence of breast or ovarian tumor are contributing towards the growth of the market.  Diabetes is another risk factor that leads to the development of endometrial cancer. According to the American Cancer Society,  endometrial cancer is four times common in diabetic women than in normal women. Such factors contribute to endometrial cancer among women.
However, factors such as high cost of diagnostic procedures, expensive treatments, and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.
Research Methodology
Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
  • Primary Research
Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
  • Secondary Research
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the global endometrial cancer market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.
Segmentation
The global endometrial cancer market is segmented on the basis of diagnosis, treatment, and end-user. The endometrial cancer market, by diagnosis, is categorized into pelvic examination, transvaginal ultrasound, endometrial biopsy, dilation and curettage (D&C), and laparoscopy. On the basis of treatment, the market is segmented into hysterectomy techniques, radiation, hormone therapy, chemotherapy, and palliative care. The hysterectomy techniques category includes open abdominal hysterectomy, total vaginal hysterectomy, total laparoscopic hysterectomy, and robotic hysterectomy. The radiation category includes external radiation and internal radiation (brachytherapy). The hormonal therapy includes progestins, tamoxifen, luteinizing hormone-releasing hormone agonists, and aromatase inhibitors. The chemotherapy segment is categorized into paclitaxel, carboplatin, doxorubicin, and cisplatin. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.     
On the basis of region, the global endometrial cancer market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Key players
Some of the key players in the global endometrial cancer market are Pfizer Inc., General Electric Company, Koninklijke Philips N.V., LUPIN, PHYTON, Bayer AG, Celgene Corporation, Johnson & Johnson, CooperSurgical Inc., LiNA Medical USA, Conceptus Inc., Hologic Inc., Karl Storz GmbH & Co. Kg, and Boston Scientific Corporation.
Regional Market Summary
The endometrial cancer market is dominated by North America owing to the rising prevalence of breast cancer. The US Breast Cancer Statistics projected 266,120 new cases of invasive breast cancer and 63,960 new cases of non-invasive breast cancer in 2018. Other factors such as increasing healthcare expenditure and increasing obesity within the female population drive the market growth in this region.
It is estimated that Europe stood second in the global endometrial cancer market owing to the increasing prevalence of ovarian cancer in this region. According to the Cancer Research UK in 2015, 7270 new cases of ovarian cancer were registered in the UK. Thus, the increasing prevalence of ovarian cancer in this region influences the growth of this market in this region.
Asia-Pacific was projected to be the fastest growing region for the global endometrial cancer market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. According to the American Diabetes Association, diabetes in South Asia is expected to rise by 150% from 2000 to 2035. This provides a favorable background for the market to grow.
The Middle East and Africa holds the least share in the global endometrial cancer market due to the presence of stringent government policies and poor economies. However, the market is expected to witness growth due to the rising healthcare expenditure, growing private sector in the healthcare domain, and insurance coverage in the Middle East.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Comments (Atom)